With the world continuing to pack on pounds, there is an urgent need for effective weight management in an increasingly health-conscious world. According to an industry report, the global weight-loss market is projected to surge to $399.3 billion by 2032, expanding at a compound annual growth rate (CAGR) of 10.3%. The race for the ultimate weight-loss solution is more intense than ever.
Leading the weight-loss gold rush are healthcare giants Novo Nordisk (NVO) and Eli Lilly (LLY) with their injectable GLP-1 drugs, Wegovy and Zepbound. Meanwhile, oral weight-loss drugs are emerging as new darlings of the dieting domain, offering a painless alternative to the sting of injections.
